Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
paradigm_report_works_22122023
10.1016_j.parkreldis.2022.02.017
6
2022
47
51
article
97
cc-by-nc-nd
http://www.prd-journal.com/article/S1353802022000505/pdf
Parkinsonism & Related Disorders
Elsevier BV
Robert A. Hauser
Hadas Barkay
Amanda Wilhelm
Maria Wieman
Juha‐Matti Savola
Mark Forrest Gordon
True
10.1016/j.parkreldis.2022.02.017
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our
Terms of Service and Privacy Policy.